Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GABRP | O00591 | 4/20 | 0.46 |
| ▸ | GABRD | O14764 | 4/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.46 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.46 |
| ▸ | GABRE | P78334 | 4/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.46 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.46 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.46 |
| ▸ | GABRQ | Q9UN88 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736555 | 0.84 | TDP1 (0.43) | MAPTTDP1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL1680324 | 0.82 | NAPRT (0.42) | MAPTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL1312979 | 0.81 | POLB (0.57) | MAPTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL30940155 | 0.81 | TDP1 (0.66) | MAPTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL21339634 | 0.81 | TDP1 (0.66) | MAPTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL4299384 | 0.80 | MAPT (0.50) | MAPTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL24892184 | 0.80 | NAPRT (0.40) | MAPTGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL21805908 | 0.80 | FOLH1 (0.50) | NAPRTALDH1A1 | |
| SCHEMBL30183367 | 0.80 | NAPRT (0.40) | MAPTGABRPGABRDGABRA1GABRB1 | |
| Hydrochloric Acid SCHEMBL20552328 | 0.79 | TDP1 (0.64) | MAPTGABRPGABRDGABRA1GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3619205-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2022-04-06 | — | — | EP | disclosed |
| US-10954252-B1 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10954252-B1 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2021-03-23 | — | — | US | disclosed |
| EP-3619205-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203235-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2018-11-08 | — | — | WO | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | NAKAMOTO KAZUTAKA | 2011-08-11 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932272-B2 | Antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1782811-A1 | NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1669348-A1 | NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND | Eisai Co., Ltd. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195999-A1 | NOVEL ANTIFUNGAL AGENT CONTAINING HETEROCYCLIC COMPOUND | ERG28, CYP51A1, XPO1 | MAPT 4076/4885GABRP 2017/4885GABRD 3749/4885 |
| US-20090227799-A1 | Novel Antimalarial Agent Containing Heterocyclic Compound | XPO1, THPO, G6PD | MAPT 4227/4885GABRP 4320/4885GABRD 4831/4885 |
| US-20070105943-A1 | Novel antifungal agent containing heterocyclic compound | ERG28, DPM1, CYP51A1 | MAPT 4111/4885GABRP 2375/4885GABRD 3990/4885 |
| US-10954252-B1 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, REV1, POLR2E | MAPT 1659/4885GABRP 3394/4885GABRD 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.